The results of the trial suggested that olaparib 400mg twice daily extended progression free survival (PFS) by RECIST compared to placebo Median PFS: 8.4 vs 4.8 months respectively.
Olaparib also prolonged the secondary endpoint of time to progression (TTP) by CA-125 or RECIST Median TTP 8.3 vs 3.7 months respectively.
AstraZeneca Medical Science director Jane Robertson said these results are encouraging as they suggest that olaparib may have a positive effect on PFS in women with serous ovarian cancer, and may be a valuable therapeutic option for this aggressive form of cancer.